Stock Performance and Market Context
On 6 Mar 2026, Lupin Ltd. recorded its highest price in the past year at Rs.2368, surpassing its previous 52-week low of Rs.1774. The stock has demonstrated resilience with a consecutive two-day gain, delivering a cumulative return of 1.75% during this period. Today’s performance outpaced the Pharmaceuticals & Biotechnology sector by 0.51%, signalling relative strength amid a broader market environment where the Sensex opened lower at 79,658.99 and was trading down 0.44% at 79,665.29.
Notably, Lupin is trading above all key moving averages – 5-day, 20-day, 50-day, 100-day, and 200-day – indicating a strong upward trend. In contrast, the Sensex remains below its 50-day moving average, although the 50DMA is positioned above the 200DMA, suggesting mixed signals for the broader market.
Financial Metrics Supporting the Rally
Lupin’s recent price surge is underpinned by solid financial fundamentals. The company has maintained a low average Debt to Equity ratio of 0.10 times, reflecting prudent capital management. Its net sales have grown at an annual rate of 11.42%, while operating profit margins stand robustly at 33.60%, highlighting operational efficiency.
Quarterly results have been consistently positive for the last three quarters, with the latest figures showing a Profit Before Tax (excluding other income) of Rs.1,833.91 crores, marking a 43.6% increase compared to the previous four-quarter average. Net sales for the quarter reached a record Rs.7,167.52 crores, further reinforcing the company’s growth trajectory.
Strong Returns and Valuation Metrics
The company’s Return on Capital Employed (ROCE) for the half-year period stands at an impressive 22.22%, while Return on Equity (ROE) is at 22%, indicating efficient utilisation of shareholder funds. Lupin’s Price to Book Value ratio of 5.4 suggests an attractive valuation, especially considering the stock trades at a discount relative to its peers’ historical averages.
Over the past year, Lupin has generated a total return of 15.93%, significantly outperforming the Sensex’s 7.16% return. Profit growth has been even more pronounced, rising by 73.5% over the same period, resulting in a low PEG ratio of 0.3, which points to favourable earnings growth relative to its price.
Our latest weekly pick is out! This Large Cap from Steel/Sponge Iron/Pig Iron delivered with target price and complete analysis. See what makes this week's selection special!
- - Latest weekly selection
- - Target price delivered
- - Large Cap special pick
Institutional Confidence and Market Standing
Institutional investors hold a significant 47.08% stake in Lupin Ltd., reflecting confidence from entities with extensive analytical resources. This level of institutional ownership often correlates with a stable shareholder base and can contribute to sustained price momentum.
Within the broader market, Lupin is distinguished by its high MarketsMojo Mojo Score of 78.0 and a current Mojo Grade of Buy, upgraded from Strong Buy on 16 Feb 2026. The company ranks among the top 1% of over 4,000 stocks rated by MarketsMojo, positioned 12th among mid-cap companies and 40th across the entire market, underscoring its strong fundamentals and market reputation.
Consistent Outperformance Over Time
Beyond the recent price milestone, Lupin has demonstrated consistent returns over the last three years. It has outperformed the BSE500 index in each of the past three annual periods, reinforcing its status as a resilient and steadily growing stock within the Pharmaceuticals & Biotechnology sector.
Thinking about Lupin Ltd.? Our real-time Verdict report breaks down everything – from financial health and peer comparison to technical signals and fair valuation for this mid-cap stock!
- - Real-time Verdict available
- - Financial health breakdown
- - Fair valuation calculated
Summary of Key Indicators
Lupin Ltd.’s recent surge to Rs.2368 is supported by a combination of strong financial results, favourable valuation metrics, and sustained institutional backing. The stock’s upward trajectory is further validated by its position above all major moving averages and its outperformance relative to both sector peers and the broader market index.
With a market cap grade of 2 and a day change of 0.31%, Lupin continues to demonstrate steady growth and resilience in a competitive sector. Its consistent quarterly performance and robust profitability metrics provide a solid foundation for the current momentum observed in the stock price.
Conclusion
Lupin Ltd.’s achievement of a new 52-week high at Rs.2368 marks a significant milestone reflecting the company’s strong fundamentals and positive market sentiment. The stock’s performance over the past year, combined with its attractive valuation and institutional support, highlights its standing as a key player in the Pharmaceuticals & Biotechnology sector. This milestone underscores Lupin’s capacity to maintain upward momentum amid a fluctuating market environment.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
